Article Details
Retrieved on: 2020-01-25 07:03:45
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>ValuEngine upgraded shares of Seres Therapeutics (NASDAQ:MCRB) from a hold rating to a buy rating in a research note published on Friday, ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here